NO20013941L - Polynukleotider med forkortet kjede og fremgangsmåte ved fremstillingen derav - Google Patents

Polynukleotider med forkortet kjede og fremgangsmåte ved fremstillingen derav

Info

Publication number
NO20013941L
NO20013941L NO20013941A NO20013941A NO20013941L NO 20013941 L NO20013941 L NO 20013941L NO 20013941 A NO20013941 A NO 20013941A NO 20013941 A NO20013941 A NO 20013941A NO 20013941 L NO20013941 L NO 20013941L
Authority
NO
Norway
Prior art keywords
preparation
short
chain polynucleotides
chain
same
Prior art date
Application number
NO20013941A
Other languages
English (en)
Norwegian (no)
Other versions
NO20013941D0 (no
Inventor
Shinji Matsuyama
Kouichi Ishiyama
Junzo Seki
Tadaaki Ohgi
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of NO20013941D0 publication Critical patent/NO20013941D0/no
Publication of NO20013941L publication Critical patent/NO20013941L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20013941A 1999-02-15 2001-08-14 Polynukleotider med forkortet kjede og fremgangsmåte ved fremstillingen derav NO20013941L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP3596399 1999-02-15
PCT/JP2000/000778 WO2000047601A1 (fr) 1999-02-15 2000-02-14 Polynucleotides a chaine raccourcie et procede de preparation correspondant

Publications (2)

Publication Number Publication Date
NO20013941D0 NO20013941D0 (no) 2001-08-14
NO20013941L true NO20013941L (no) 2001-08-14

Family

ID=12456623

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013941A NO20013941L (no) 1999-02-15 2001-08-14 Polynukleotider med forkortet kjede og fremgangsmåte ved fremstillingen derav

Country Status (14)

Country Link
US (2) US6780429B1 (zh)
EP (1) EP1153931B1 (zh)
KR (1) KR100455814B1 (zh)
CN (1) CN1194002C (zh)
AT (1) ATE299885T1 (zh)
AU (1) AU2460900A (zh)
BR (1) BR0008227A (zh)
CA (1) CA2359674A1 (zh)
DE (1) DE60021354T2 (zh)
ID (1) ID29546A (zh)
NO (1) NO20013941L (zh)
RU (1) RU2238279C2 (zh)
WO (1) WO2000047601A1 (zh)
ZA (1) ZA200106701B (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6958324B2 (en) 1998-12-02 2005-10-25 Inotek Pharmaceuticals Corporation Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
US20010053763A1 (en) * 1998-12-02 2001-12-20 Andrew Salzman Method and composition for modulating an immune response
JPWO2004058959A1 (ja) * 2002-12-26 2006-04-27 日本新薬株式会社 ＰＮＰａｓｅの製造法
CA2587676A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
AU2009239655B2 (en) 2008-04-25 2014-05-22 Innate Pharma Improved TLR3 agonist compositions
EP2116602A1 (en) 2008-05-07 2009-11-11 Institut Gustave Roussy Combination products for treating cancer
CN101352422B (zh) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 河豚毒素冻干粉针制剂及其制备方法
EP2542670A2 (en) 2010-03-05 2013-01-09 President and Fellows of Harvard College Induced dendritic cell compositions and uses thereof
US9814740B2 (en) 2010-12-21 2017-11-14 Duke University Methods and compositions combining immunotherapy with monocyte activation
EP2858722B8 (en) 2012-06-08 2018-02-21 Aduro BioTech, Inc. Compostions and methods for cancer immunotherapy
WO2014088087A1 (ja) * 2012-12-06 2014-06-12 協和発酵バイオ株式会社 アジュバント用二重鎖リボ核酸
SG10201704611WA (en) 2012-12-13 2017-07-28 Aduro Biotech Inc Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
CN105358158A (zh) 2013-04-29 2016-02-24 纪念斯隆-凯特琳癌症中心 用于改变第二信使信号传导的组合物和方法
CN105377867B (zh) 2013-05-03 2019-11-12 加利福尼亚大学董事会 I型干扰素的环状二核苷酸诱导
ES2754269T3 (es) 2013-05-18 2020-04-16 Aduro Biotech Inc Composiciones y métodos de activación de la señalización dependiente del "estimulador de los genes de interferón
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
EP3027227A4 (en) 2013-07-31 2018-05-23 Memorial Sloan Kettering Cancer Center Sting crystals and modulators
JP7252627B2 (ja) 2016-12-15 2023-04-05 デューク ユニバーシティ 制御性ｂ１０細胞を枯渇させる抗体および方法並びに免疫チェックポイント阻害剤との併用における使用
EP4329761A1 (en) 2021-04-28 2024-03-06 ENYO Pharma Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692899A (en) * 1969-12-17 1972-09-19 Us Health Education & Welfare Inhibition of transplanted tumor growth by polyinosinic-polycytidylic acid in mice
US3666646A (en) * 1970-05-15 1972-05-30 Merck & Co Inc Reduction of molecular weight in polynucleotides using ultrasonic radiation
US5298614A (en) * 1986-01-06 1994-03-29 Nippon Shinyaku Co. Ltd. Size limited double stranded poly I poly(cytidylate/4-thiouridylate)
GB2207138B (en) * 1987-07-03 1992-02-05 Nippon Shinyaku Co Ltd Preparation of nucleic acid derivatives.
US6020317A (en) * 1993-02-19 2000-02-01 Nippon Shinyaku Co. Ltd. Glycerol derivative, device and pharmaceutical composition
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5886165A (en) * 1996-09-24 1999-03-23 Hybridon, Inc. Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments

Also Published As

Publication number Publication date
EP1153931A4 (en) 2002-07-17
EP1153931A1 (en) 2001-11-14
AU2460900A (en) 2000-08-29
CN1194002C (zh) 2005-03-23
ID29546A (id) 2001-09-06
BR0008227A (pt) 2001-10-30
KR20020013500A (ko) 2002-02-20
US7223857B2 (en) 2007-05-29
KR100455814B1 (ko) 2004-11-06
CN1340055A (zh) 2002-03-13
ATE299885T1 (de) 2005-08-15
WO2000047601A1 (fr) 2000-08-17
NO20013941D0 (no) 2001-08-14
DE60021354T2 (de) 2006-04-27
EP1153931B1 (en) 2005-07-20
RU2238279C2 (ru) 2004-10-20
CA2359674A1 (en) 2000-08-17
DE60021354D1 (de) 2005-08-25
US20040235044A1 (en) 2004-11-25
US6780429B1 (en) 2004-08-24
ZA200106701B (en) 2002-11-14

Similar Documents

Publication Publication Date Title
NO20013941L (no) Polynukleotider med forkortet kjede og fremgangsmåte ved fremstillingen derav
DE69915004D1 (de) 5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate
EP2201945A3 (en) Use of substituted 2-aminoacetamides for treating or ameliorating anxiety
DE69920017D1 (de) Neue form vom irbesartan, verfahren um diese form zu erhalten und sie enthaltende pharmazeutische zusammensetzungen
IN2012DE00109A (zh)
WO2002100858A3 (en) Quinuclidine-substituted heteroaromatic compounds as ligands at nicotinic acetylcholine receptors
DE60239842D1 (de) Verfahren zur Herstellung von 10,11-dihydro-10-oxo-5h-dibenzoÄb,fÜazepin-5-carboxamid
DE69901519D1 (de) Verfahren zur Herstellung von 2,2'-bis (Hydroxymethyl)alkansäure
DE50006245D1 (de) Verfahren zur herstellung von (1,1':4',1'')-terphenylvebindungen
DE60222806D1 (de) Verfahren zur herstellung von (1,4,5)-oxadiazepinderivaten
NO900186D0 (no) Kondenserte benzazepiner.
DE69913635D1 (de) Verfahren zur Herstellung von 1,3-Dialkyl-2-Imidazolinonderivaten
DE69903610D1 (de) Verfahren zur Herstellung von 5,5'-bi-1H-Tetrazol-Salz
DE60104789D1 (de) Verfahren zur Herstellung von 2,4,5-Trialkylbenzaldehyden
DZ2770A1 (fr) Procédé de préparation de 1h-indol-3 glyoxamides substituées en position 4.
DE69510798D1 (de) Verfahren zur herstellung von kalziumsalzen von [s,s]-äthylendiamin- n,n'-dibernsteinsäure
DE60230097D1 (de) Verfahren zur herstellung von 1,5-diaminonaphthalinen
DE59900401D1 (de) Verfahren zur Herstellung von 1,3-Dimethyl-imidazolium-4-carboxylat
DE50006244D1 (en) Neue substituierte 3-phenoxy- und 3-phenylalkyloxy-2-phenyl-propylamine
DE60115538D1 (de) Verfahren zur Herstellung von hochreinen 5,5'-bi-1H-Tetrazoldiammoniumsalzen
IL154915A0 (en) Method for producing chiral compounds
DE59812284D1 (de) Verfahren zur Herstellung von 4-Amino-2,2,6,6-tetramethyl-piperidin
DE50107987D1 (de) Verfahren zur herstellung von 2,3,5,6-tetrahalogen-xylylidenverbindungen
DE60143350D1 (de) Verfahren zur herstellung von 1,3-dialkyl-2-imidazolidinon-derivaten
DE69825325D1 (de) Verfahren zur Herstellung von 3,3',5,5'-Tetra-t-Butylbiphenol

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application